*Editor*

We would like to thank Mukherjee and colleagues[1](#bjs11648-bib-0001){ref-type="ref"} for their insightful comment on our recently published Leading Article[2](#bjs11648-bib-0002){ref-type="ref"}.

As the authors correctly pointed out, little is known of the effect of SARS‐CoV‐2 on the pancreas, although some mechanisms can explain it and justify the clinical presentation observed. Data on COVID‐19 and knowledge of the disease course are evolving rapidly, justifying the fact that many grey areas exist. Indeed, the authors of a recent pathological report from China found that, even if the damage was located predominantly in the lungs, there were alterations in several other organs, including heart, spleen, liver and bone marrow, with degeneration of some islet cells in the pancreas[3](#bjs11648-bib-0003){ref-type="ref"}. Moreover, the rate of patients presenting with abdominal symptoms might have been influenced by the actual number of individuals tested. Interestingly, according to a study performed at Humanitas Hospital, of the first 100 patients admitted to the COVID‐19 ward, approximately 15 per cent had diarrhoea; we cannot anticipate how many had increased amylase or lipase on laboratory tests at admission, as data are under analysis (S. Danese, unpublished).

In light of these observations and the comment of Mukherjee *et al*.[1](#bjs11648-bib-0001){ref-type="ref"}, we suggest it is important to capture information on this aspect of the disease by means of ongoing studies on COVID‐19 patients, especially those dealing with surgery during the pandemic. The COVIDSurg Initiative is a collaborative research group aimed at clarifying the outcome and features of patients undergoing surgery while COVID‐19‐positive; several studies are planned, with international collection of data prospectively (<https://globalsurg.org/covidsurg/>). It is likely that similar initiatives might shed some light on abdominal symptoms and involvement of the gastrointestinal tract associated with COVID‐19.
